Immune Therapeutics Inc (IMUN) 0.1000 $IMUN Immune

New Post Public Reply Private Reply Replies (0) Message Board

Sep 15, 2016 at 7:07 AM

Immune Therapeutics Inc (IMUN) 0.1000 $IMUN

Immune Therapeutics, Inc., Through Its Wholly Owned Subsidiary TNI BioTech International, Ltd., Initiates Clinical Trial In Malawi With LDN For The Prevention Of Cervical Cancer
PR Newswire - Tue Aug 23, 12:00PM CDT
Immune Therapeutics, Inc. (OTCQB-IMUN) ("IMUN"

, headquartered in Orlando, Florida, is a clinical-stage biopharmaceutical company involved in the commercialization, manufacturing, distribution and marketing of its novel immunotherapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system.

Lodonal(TM) Expected to Receive International Exposure at the World Health Assembly, one of the World's Leading Health Forums
PR Newswire - Thu May 19, 8:30AM CDT
Immune Therapeutics, Inc. (O

Immune Therapeutics, Inc. Provides Drug Development Program Status Update on Methionine-Enkelphine ("MENK"

in China
PR Newswire - Mon Apr 11, 8:54AM CDT
Immune Therapeutics, Inc. (OTCQB: IMUN); a clinical-stage international biotechnology company providing immunotherapy solutions for the treatment of diseases, autoimmune diseases, and cancer, announced today it is providing shareholders with a status update of Immune Therapeutics, Inc.'s (IMUN) drug development program in China with long-term partner Hubei Qianjiang Pharmaceutical Co. Ltd (Qianjiang).

Immune Therapeutics, Inc. Announced the Completion of the Bridging Trial
ACCESSWIRE - Thu Jan 21, 8:45AM CST
Company Also Announced the Submission of Lodonal(TM) Data for Review in Connection with the New Drug Application to NAFDAC for Use as an Immune Booster and Adjunct Treatment for Human Immunodeficiency Virus

Immune Therapeutics, Inc., announced the completion of the bridging trial and submission of Lodonal(TM)
ACCESSWIRE - Thu Jan 21, 5:00AM CST
Data for review in connection with the New Drug Application to NAFDAC for use as an immune booster and adjunct treatment for Human Immunodeficiency Virus

Immune Therapeutics Inc. To Present at JP Morgan Health Conference
ACCESSWIRE - Mon Jan 11, 2:30PM CST
ORLANDO, FL / ACCESSWIRE / January 11, 2016 / Immune Therapeutics Inc. (OTCQB: IMUN) CEO, Noreen Griffin, will be making a presentation at today's JP Morgan Health Conference at the Fairmont hotel in San Francisco.

Immune Therapeutics Inc. Provides Update on Clinical Trial of Lodonal as an Immune-System Regulating Agent in Subjects with Compromised Immune Systems
ACCESSWIRE - Wed Oct 07, 5:21PM CDT
ORLANDO, FL / ACCESSWIRE / October 7, 2015 / Immune Therapeutics Inc. a specialty biopharmaceutical company (OTCQB: IMUN) today provided an update on the ongoing clinical trial of Lodonal in Nigeria.

Immune Therapeutics Adds Experienced New Board Member Saiid Zarrabian
ACCESSWIRE - Wed Oct 07, 5:18PM CDT
ORLANDO, FL / ACCESSWIRE / October 7, 2015 / Immune Therapeutics, Inc., a U.S. public company (OTCQB: IMUN), announces the appointment of Saiid Zarrabian as Immune's newest board member.
SNMX: 4.24 (-0.20)

Immune Therapeutics Inc, and ARAH Pharma Granted License to Import Lodonal to Nigeria
ACCESSWIRE - Wed Aug 12, 1:05PM CDT
To Be Used As an Adjunct Treatment for HIV/AIDS and Opportunistic Infections by Nigerian National Agency for Food and Drug Administration and Control

Immune Therapeutics Inc. in partnership with GB Pharma and AHAR sign LOI with Fidson Healthcare Plc for the distribution of Lodonal in Nigeria.
GlobeNewswire - Mon Aug 03, 8:27AM CDT
via PRWEB - An agreement between Immune Therapeutics GB Pharma/AHAR with Fidson Healthcare will enable Fidson marketing, sales, customer support, and technical assistance organization to promote LodonalTM in Nigeria. This will elevate Immune Therapeutics and GB Pharma/AHAR distribution network to the next level. The distribution will become effective, upon completion of the ongoing NAFDAC approved 90‐day Bridging trial evaluating the efficacy and safety of LodonalTM.

ClearTrust, LLC is Immune Therapeutics' New Transfer Agent and Support Provider
PR Newswire - Mon Jan 26, 2:44PM CST
Dear Immune Therapeutics, Inc. (OTC-BB: IMUN) Shareholder:

Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc.
PR Newswire - Fri Jan 23, 2:15PM CST
Immune Therapeutics, Inc. (OTC-BB: IMUN) today announced the signing of the agreement with KRS Global Biotechnology, Inc. for the compounding, packaging and distributing of its naltrexone tablets. The tablets will be compounded for shipment in the United States.

Immune Therapeutics, Inc. Announces Appointment of New Director and Acceptance of Election by Director
PR Newswire - Wed Jan 21, 9:00AM CST
Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the manufacture, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system, today announced that Vincent Butta, a new director appointed to fill a vacancy, and Edward Teraskiewicz, a director elected at the 2014 Annual Meeting of Shareholders, joined the Board on January 13, 2015.

Immune Therapeutics Inc. Announces Appointment of New President and Chief Operating Officer
PR Newswire - Wed Jan 14, 10:01AM CST
Immune Therapeutics Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the manufacture, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system, today announced the appointment of Seth Elliot as President and Chief Operating Officer.

The Jack Brewer Foundation and Immune Therapeutics Inc. Announce Medical Equipment Donation Program for the Prevention of Cervical Cancer in Africa to be Unveiled Today at the United Nations
PR Newswire - Thu Jan 08, 9:00AM CST
Immune Therapeutics Inc. (OTC:BB IMUN) - The Jack Brewer Foundation (JBF Worldwide) and Immune Therapeutics, Inc. announced today a first-of-its-kind donation program to improve access to treatment to prevent cervical cancer that until now has been unavailable to the women of Malawi, Africa.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Where Winds Meet Celebrates 1st Anniversary With New Region

A Staggering Universe Deepens: Hutuo's Introduction Just when you think you've seen it all, NetEase Games and Everstone Studio go and launch Hutuo, a compelling addition to the already sprawling universe of Where Winds Meet. On the occasion of its first global anniversary, this epic Wuxia ARPG throws players into the mud-soaked, steel-clashing chaos of a warzone, testing...

OI Investors Crack Down: Class Action Filing Looms

O-I Glass Under Fire: The Glass Containers Giant Stumbles If you’ve been watching the ticker for O-I Glass, Inc. (NYSE:OI), you know it’s been a rocky road lately. We’re knee-deep in another saga of corporate promises meeting harsh reality. The novel here isn’t just the $1 trillion industry O-I Glass plays in, but the speed at which its fortunes seem to be...

Biel Crystal's AI Vision Earns Forbes Recognition

What's Cookin' in Smart Manufacturing? Sometimes, the big news isn’t just about the dollars—it’s about who’s turning heads with their tech wizardry. That's what's happening over at Biel Crystal. Crafting Smarter Manufacturing This Hong Kong-based dynamo isn't your run-of-the-mill manufacturer. Biel Crystal, with its jaw-dropping setup of over 100,000 employees...

Aluminum Fluoride Market to Hit $3.3B by 2031

Eye on the Aluminum Fluoride Surge Cracking open the numbers, the aluminum fluoride market is projected to swell from $2.48 billion in 2026 to a hefty $3.30 billion by 2031, trucking along at a CAGR of 5.9%. That's no small potatoes in the world of industrial materials. Scratch the surface, and you’ll see what's fueling this climb—think of it as a bellwether for...

Will Hair Loss Drugs Challenge Transplant Clinics?

Emerging Treatments Stir Up Hair Loss Scene You ever get the feeling we're on the brink of something big? That's where we are with hair loss treatments, folks. As of late 2026, new drugs are making waves in clinical trials, but they’re not yet giving hair transplant clinics any sleepless nights. Smile Hair Clinic's co-founders, Dr. Mehmet Erdo?an and Dr. Gökay Bilgin,...

Revving Up: TIER IV and Komatsu's Bold Auto Move

Steering Toward a Driverless Future When you think of technology leaders, dump trucks might not be the first thing that comes to mind. But here we are, with TIER IV and Komatsu sparking up a collaboration to drive their heavy-duty fleet straight into the future. We're talking autonomous driving systems for three brawny dump truck models—the HD785, HD605, and...

Procon Uses Robotics to Revamp Cruise Terminal 5

Building Bigger with Robotics at Port Canaveral Robots on a construction site sounds like sci-fi, right? But it's the reality at Port Canaveral's Cruise Terminal 5, where Procon is rolling out its robotic tech magic. This ain't your everyday wrench-and-spanner job; we're talking remote-controlled bots capturing 360-degree images. “Regular reality capture can help teams...

Schools Reimagine Yearbooks with Interactive Archives

Revamping School Memories for the Tech Age In a world where every facet of life is digitally chronicled, it's about time schools got on board the archival train in a dynamic way. That's where Rocket Alumni Solutions steps in, breathing fresh life into those dust-gathering yearbooks and sepia-toned photos. Tackling History Collection by Collection Think you can throw a...

Natura's 3Q26 Performance: Navigating Bottlenecks and Potential

Unexpected Performance Amidst Challenging Circumstances I'll tell you, navigating through operational bottlenecks is no small feat, but Natura seems to be brewing its own survival recipe. They reported a net income of BRL 49 million in the third quarter of 2026, clawing back from a net loss of BRL 119 million in the previous year. That's no magic trick; it's a reflection...

Biodiversity Monitoring Poised for $11.39 Billion Boom

A Billion-Dollar Market on the Rise Picture this: you're watching the world make a monumental shift towards sustainability in real-time. The biodiversity monitoring market is on a gallop, poised to grow from a modest USD 7.17 billion in 2026 to a hearty USD 11.39 billion by 2031. That's a CAGR of 9.7%—a pace that soothes the nerves of any investor weary of the whims of...